Indication: Prostate Cancer

Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer

Metastatic (Stage IV)

Sub-indication: Biomarker study of DNA-repair Defects in Men With Metastatic Prostate Cancer

Line of Therapy: Metastatic Prostate Cancer

Observational

Principal Investigator: Arash Rezazadeh, M.D.
Norton Cancer Institute

Sponsor: Janssen Research & Development

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.